Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com
StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report released on Saturday. The brokerage set a "sell" rating on the biotechnology company's stock.
斯托克新闻网在周六发布的一份报告中开始报道基因生物科学公司(纳斯达克代码:GNCA-GET评级)的股票。该经纪公司对这家生物技术公司的股票设定了“卖出”评级。
A number of other equities research analysts have also weighed in on GNCA. Robert W. Baird decreased their target price on Genocea Biosciences from $8.00 to $3.00 in a research report on Monday, April 11th. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Finally, Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research report on Friday, April 29th.
其他一些股票研究分析师也加入了对GNCA的看法。罗伯特·W·贝尔德在4月11日星期一的一份研究报告中将他们对Genocea Biosciences的目标价从8.00美元下调至3.00美元。在4月29日星期五发布的一份研究报告中,HC Wainwright将Genocea Biosciences的评级从买入下调至中性。最后,Stifel Nicolaus在4月29日星期五的一份研究报告中将Genocea Biosciences的评级从“买入”下调至“持有”。
Genocea Biosciences Stock Performance
Genocea Bioscions股票表现
Shares of NASDAQ GNCA opened at $0.02 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. The business has a fifty day simple moving average of $0.07 and a two-hundred day simple moving average of $0.64. The firm has a market cap of $881,010.00, a PE ratio of -0.02 and a beta of 2.26. Genocea Biosciences has a twelve month low of $0.01 and a twelve month high of $2.24.
上周五,纳斯达克大中华区的股价开盘报0.02美元。该公司的速动比率为1.35,流动比率为1.35,债务权益比为0.24。该业务的50日简单移动均线切入位为0.07美元,200日简单移动均线切入位为0.64美元。该公司市值为881,010.00美元,市盈率为-0.02,贝塔系数为2.26。Genocea Biosciences的12个月低点为0.01美元,12个月高位为2.24美元。
Insider Transactions at Genocea Biosciences
Genocea Biosciences的内幕交易
Institutional Inflows and Outflows
机构资金流入和流出
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC bought a new stake in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Hedge funds and other institutional investors own 59.25% of the company's stock.
一家对冲基金最近购买了Genocea Biosciences股票的新股份。根据Acadian Asset Management LLC向美国证券交易委员会(Securities And Exchange Commission)的最新披露,该公司在第四季度购买了Genocea Biosciences,Inc.(纳斯达克代码:GNCA-GET Rating)的新股。该机构投资者买入了这家生物技术公司21,741股股票,价值约25,000美元。对冲基金和其他机构投资者持有该公司59.25%的股票。
About Genocea Biosciences
关于Genocea生物科学
(Get Rating)
(获取评级)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences,Inc.是一家生物制药公司,发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS,该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- MarketBeat:回顾一周7/11-7/15
- Coupang的股票即将翻身吗?
- 你的投资组合中应该有这两家银行吗?
- Verint Systems Stock是一场客户互动活动
- 为什么Shopify股票拆分...并一如既往地适合购物
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。